Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Immunic, Inc. received a Schedule 13G reporting beneficial ownership of its common stock by OrbiMed entities. OrbiMed Advisors LLC and OrbiMed Genesis GP LLC each report beneficial ownership of 756,860 shares of common stock, representing 5.3% of the class, with shared voting and dispositive power over these shares. OrbiMed Capital LLC reports beneficial ownership of 388,540 shares, representing 2.8% of the class, with sole voting and dispositive power. The reporting persons also note holding 7.8% of the shares of common stock issuable upon exercise of warrants on behalf of other persons, over which OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power through a management committee whose members disclaim beneficial ownership.
Key Figures
Beneficial ownership – OrbiMed Advisors LLC:756,860 sharesBeneficial ownership – OrbiMed Genesis GP LLC:756,860 sharesBeneficial ownership – OrbiMed Capital LLC:388,540 shares+3 more
6 metrics
Beneficial ownership – OrbiMed Advisors LLC756,860 sharesImmunic common stock; represents 5.3% of the class
Beneficial ownership – OrbiMed Genesis GP LLC756,860 sharesImmunic common stock; represents 5.3% of the class
Beneficial ownership – OrbiMed Capital LLC388,540 sharesImmunic common stock; represents 2.8% of the class
Warrant-related holdings7.8%Shares of Immunic common stock issuable upon exercise of warrants held on behalf of others
Shared voting power – OrbiMed Advisors LLC756,860 sharesImmunic common stock with shared voting and dispositive power
Sole voting power – OrbiMed Capital LLC388,540 sharesImmunic common stock with sole voting and dispositive power
Key Terms
beneficial ownership, shared voting power, sole dispositive power, Schedule 13G, +1 more
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"6 | Shared Voting Power 756,860.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
sole dispositive powerfinancial
"7 | Sole Dispositive Power 388,540.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13Gregulatory
"The Reporting Persons filed this Schedule 13G regarding ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Investment Company Act of 1940regulatory
"investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Immunic, Inc. (IMUX) does OrbiMed Advisors LLC report?
OrbiMed Advisors LLC reports beneficial ownership of 756,860 Immunic common shares, representing 5.3% of the class, with shared voting and dispositive power over these shares as disclosed in the Schedule 13G.
How many Immunic (IMUX) shares does OrbiMed Genesis GP LLC beneficially own?
OrbiMed Genesis GP LLC reports beneficial ownership of 756,860 Immunic common shares, or 5.3% of the class, with shared voting and dispositive power over the same block of shares as OrbiMed Advisors LLC.
What is OrbiMed Capital LLC’s ownership percentage in Immunic (IMUX)?
OrbiMed Capital LLC reports beneficial ownership of 388,540 Immunic common shares, representing 2.8% of the class, and has sole voting and dispositive power over these shares according to the filing.
What does the Schedule 13G say about warrants related to Immunic (IMUX)?
The reporting persons state they hold 7.8% of the shares of Immunic common stock issuable upon exercise of warrants in the aggregate on behalf of other persons entitled to dividends or sale proceeds.
Who exercises investment and voting power over the Immunic (IMUX) warrant shares?
OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the Immunic common stock issuable upon exercise of warrants through a management committee including Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu.
Do OrbiMed management committee members claim beneficial ownership of Immunic (IMUX) shares?
The filing states that committee members Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu each disclaim beneficial ownership of the Immunic common stock issuable upon exercise of warrants reported.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Immunic, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
4525EP101
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
4525EP101
1
Names of Reporting Persons
OrbiMed Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
756,860.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
756,860.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
756,860.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
4525EP101
1
Names of Reporting Persons
OrbiMed Genesis GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
756,860.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
756,860.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
756,860.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
4525EP101
1
Names of Reporting Persons
OrbiMed Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
388,540.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
388,540.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
388,540.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.8 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Immunic, Inc.
(b)
Address of issuer's principal executive offices:
1200 Avenue of the Americas, Suite 200, New York, NY 10036
Item 2.
(a)
Name of person filing:
OrbiMed Advisors LLC
OrbiMed Genesis GP LLC
OrbiMed Capital LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor, New York, NY 10022
(c)
Citizenship:
Please refer to Item 4 on each cover sheet for each filing person.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
4525EP101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
OrbiMed Advisors LLC: 756,860
OrbiMed Genesis GP LLC: 756,860
OrbiMed Capital LLC: 388,540
(b)
Percent of class:
OrbiMed Advisors LLC: 5.3%
OrbiMed Genesis GP LLC: 5.3%
OrbiMed Capital LLC: 2.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Genesis GP LLC: 0
OrbiMed Capital LLC: 388,540
(ii) Shared power to vote or to direct the vote:
OrbiMed Advisors LLC: 756,860
OrbiMed Genesis GP LLC: 756,860
OrbiMed Capital LLC: 0
(iii) Sole power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Genesis GP LLC: 0
OrbiMed Capital LLC: 388,540
(iv) Shared power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 756,860
OrbiMed Genesis GP LLC: 756,860
OrbiMed Capital LLC: 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Persons hold 7.8% of the shares of Common Stock issuable upon the exercise of warrants in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock issuable upon the exercise of warrants through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock issuable upon the exercise of warrants reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
